In a recent small-scale trial, Novo Nordisk's older obesity drug liraglutide demonstrated a significant biological impact on patients with Alzheimer's disease. The study, which marks a notable step in the potential repurposing of obesity medications for neurological conditions, showed promising effects, though further research is needed to validate these findings. The trial results underscore the ongoing exploration of innovative treatment avenues in the fight against Alzheimer's.

For more details, visit Reuters or Drug Discovery Trends.